John D Lambris

List of Publications by Year
in descending order

521 papers	49,256 citations	1094 112 h-index	2375 198 g-index
608 all docs	608 docs citations	608 times ranked	38494 citing authors

#	Article	IF	Citations
1	Complement: a key system for immune surveillance and homeostasis. Nature Immunology, 2010, 11, 785-797.	7.0	2,990
2	The Classical Complement Cascade Mediates CNS Synapse Elimination. Cell, 2007, 131, 1164-1178.	13.5	2,567
3	Low-Abundance Biofilm Species Orchestrates Inflammatory Periodontal Disease through the Commensal Microbiota and Complement. Cell Host and Microbe, 2011, 10, 497-506.	5.1	916
4	Generation of C5a in the absence of C3: a new complement activation pathway. Nature Medicine, 2006, 12, 682-687.	15.2	845
5	Complement evasion by human pathogens. Nature Reviews Microbiology, 2008, 6, 132-142.	13.6	654
6	Modulation of the antitumor immune response by complement. Nature Immunology, 2008, 9, 1225-1235.	7.0	612
7	Molecular Intercommunication between the Complement and Coagulation Systems. Journal of Immunology, 2010, 185, 5628-5636.	0.4	605
8	Drusen complement components C3a and C5a promote choroidal neovascularization. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2328-2333.	3.3	584
9	Complement and tissue factorâ€“enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. Journal of Clinical Investigation, 2020, 130, 6151-6157.	3.9	580
10	The Role of Complement in Inflammatory Diseases From Behind the Scenes into the Spotlight. American Journal of Pathology, 2007, 171, 715-727.	1.9	563
11	Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. Journal of Clinical Investigation, 2003, 112, 1644-1654.	3.9	537
12	Complement and coagulation: strangers or partners in crime?. Trends in Immunology, 2007, 28, 184-192.	2.9	533
13	The complement system in teleosts. Fish and Shellfish Immunology, 2002, 12, 399-420.	1.6	511
14	Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunological Reviews, 2001, 180, 35-48.	2.8	449
15	Complement-targeted therapeutics. Nature Biotechnology, 2007, 25, 1265-1275.	9.4	427
16	Complement in disease: a defence system turning offensive. Nature Reviews Nephrology, 2016, 12, 383-401.	4.1	427
17	Complement as a target in COVID-19?. Nature Reviews Immunology, 2020, 20, 343-344.	10.6	426
18	Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10837-10842.	3.3	417

#	Article	IF	Citations
19	A Novel C5a Receptor-Tissue Factor Cross-Talk in Neutrophils Links Innate Immunity to Coagulation Pathways. Journal of Immunology, 2006, 177, 4794-4802.	0.4	412
20	Complement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms. Journal of Immunology, 2013, 190, 3831-3838.	0.4	412
21	Interactions between coagulation and complementâ€"their role in inflammation. Seminars in Immunopathology, 2012, 34, 151-165.	2.8	393
22	The Proinflammatory Mediators C3a and C5a Are Essential for Liver Regeneration. Journal of Experimental Medicine, 2003, 198, 913-923.	4.2	385
23	The role of complement in biomaterial-induced inflammation. Molecular Immunology, 2007, 44, 82-94.	1.0	384
24	Innate immune responses to trauma. Nature Immunology, 2018, 19, 327-341.	7.0	377
25	Novel mechanisms and functions of complement. Nature Immunology, 2017, 18, 1288-1298.	7.0	364
26	Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease): An Update. Journal of the American Society of Nephrology: JASN, 2005, 16, 1392-1403.	3.0	354
27	Structure of C3b reveals conformational changes that underlie complement activity. Nature, 2006, 444, 213-216.	13.7	344
28	Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood, 2002, 100, 1869-77.	0.6	342
29	PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer. Cell, 2015, 160, 700-714.	13.5	334
30	Interaction Between the Coagulation and Complement System. Advances in Experimental Medicine and Biology, 2008, 632, 68-76.	0.8	329
31	Regulation of Toll-like receptorâ€"mediated inflammatory response by complement in vivo. Blood, 2007, 110, 228-236.	0.6	327
32	Porphyromonas gingivalis Manipulates Complement and TLR Signaling to Uncouple Bacterial Clearance from Inflammation and Promote Dysbiosis. Cell Host and Microbe, 2014, 15, 768-778.	5.1	318
33	Complement component C3 â€" The â€œSwiss Army Knifeâ€•of innate immunity and host defense. Immunological Reviews, 2016, 274, 33-58.	2.8	313
34	The renaissance of complement therapeutics. Nature Reviews Nephrology, 2018, 14, 26-47.	4.1	305
35	Protective Effects of IL-6 Blockade in Sepsis Are Linked to Reduced C5a Receptor Expression. Journal of Immunology, 2003, 170, 503-507.	0.4	301
36	Do Cryopreserved Mesenchymal Stromal Cells Display Impaired Immunomodulatory and Therapeutic Properties?. Stem Cells, 2014, 32, 2430-2442.	1.4	300

#	Article	IF	Citations
37	Structure of complement fragment C3bâ€"factor H and implications for host protection by complement regulators. Nature Immunology, 2009, 10, 728-733.	7.0	299
38	New insights into the immune functions of complement. Nature Reviews Immunology, 2019, 19, 503-516.	10.6	281
39	Complement in cancer: untangling an intricate relationship. Nature Reviews Immunology, 2018, 18, 5-18.	10.6	279
40	Complement Fragment C3a Controls Mutual Cell Attraction during Collective Cell Migration. Developmental Cell, 2011, 21, 1026-1037.	3.1	271
41	Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. Journal of Clinical Investigation, 2003, 112, 1644-1654.	3.9	266
42	Microbial manipulation of receptor crosstalk in innate immunity. Nature Reviews Immunology, 2011, 11, 187-200.	10.6	256
43	Clinical promise of next-generation complement therapeutics. Nature Reviews Drug Discovery, 2019, 18, 707-729.	21.5	253
44	The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clinical Immunology, 2020, 215, 108450.	1.4	252
45	Crosstalk pathways between Toll-like receptors and the complement system. Trends in Immunology, 2010, 31, 154-163.	2.9	248
46	Structures of C3b in Complex with Factors B and D Give Insight into Complement Convertase Formation. Science, 2010, 330, 1816-1820.	6.0	241
47	Cholesterol Crystals Induce Complement-Dependent Inflammasome Activation and Cytokine Release. Journal of Immunology, 2014, 192, 2837-2845.	0.4	236
48	New Approaches to the Treatment of Dense Deposit Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 2447-2456.	3.0	231
49	The multifunctional role of C3, the third component of complement. Trends in Immunology, 1988, 9, 387-393.	7.5	223
50	Herpes Simplex Virus Glycoprotein D Can Bind to Poliovirus Receptor-Related Protein 1 or Herpesvirus Entry Mediator, Two Structurally Unrelated Mediators of Virus Entry. Journal of Virology, 1998, 72, 7064-7074.	1.5	223
51	C3 glomerulopathy â€" understanding a rare complement-driven renal disease. Nature Reviews Nephrology, 2019, 15, 129-143.	4.1	223
52	A Novel Role of Complement: Mice Deficient in the Fifth Component of Complement (C5) Exhibit Impaired Liver Regeneration. Journal of Immunology, 2001, 166, 2479-2486.	0.4	220
53	Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression. Journal of Immunology, 2012, 189, 4674-4683.	0.4	219
54	Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. Blood, 2003, 101, 3784-3793.	0.6	217

#	Article	IF	Citations
55	The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. Journal of Experimental Medicine, 2005, 201, 567-577.	4.2	212
56	Complement in Immune and Inflammatory Disorders: Therapeutic Interventions. Journal of Immunology, 2013, 190, 3839-3847.	0.4	209
57	Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nature Immunology, 2009, 10, 721-727.	7.0	205
58	A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. Journal of Clinical Investigation, 2006, 116, 783-796.	3.9	194
59	Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clinical Immunology, 2020, 220, 108598.	1.4	191
60	Compstatin: a C3â€targeted complement inhibitor reaching its prime for bedside intervention. European Journal of Clinical Investigation, 2015, 45, 423-440.	1.7	178
61	Microbial Hijacking of Complementâ€“Toll-Like Receptor Crosstalk. Science Signaling, 2010, 3, ra11.	1.6	177
62	Identification of a C3bi-specific membrane complement receptor that is expressed on lymphocytes, monocytes, neutrophils, and erythrocytes. Journal of Experimental Medicine, 1982, 155, 96-110.	4.2	176
63	Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood, 2010, 116, 4395-4403.	0.6	174
64	Protection of host cells by complement regulators. Immunological Reviews, 2016, 274, 152-171.	2.8	173
65	Current understanding of periodontal disease pathogenesis and targets for hostâ€modulation therapy. Periodontology 2000, 2020, 84, 14-34.	6.3	173
66	Platelets Contribute to the Pathogenesis of Experimental Autoimmune Encephalomyelitis. Circulation Research, 2012, 110, 1202-1210.	2.0	172
67	Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood, 2014, 123, 2094-2101.	0.6	172
68	Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface. Biomaterials, 2005, 26, 1477-1485.	5.7	171
69	Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 Fragments for Factors B and H, complement receptors , and bovine conglutinin. Journal of Experimental Medicine, 1983, 158, 334-352.	4.2	166
70	Innate immunity activation on biomaterial surfaces: A mechanistic model and coping strategies. Advanced Drug Delivery Reviews, 2011, 63, 1042-1050.	6.6	163
71	Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood, 2010, 116, 1002-1010.	0.6	159
72	Complement diversity: a mechanism for generating immune diversity?. Trends in Immunology, 1998, 19, 519-523.	7.5	158

#	Article	IF	Citations
73	Evolution and diversity of the complement system of poikilothermic vertebrates. Immunological Reviews, 1998, 166, 39-57.	2.8	155
74	C3a and C3b Activation Products of the Third Component of Complement (C3) Are Critical for Normal Liver Recovery after Toxic Injury. Journal of Immunology, 2004, 173, 747-754.	0.4	155
75	The Role of Complement in Tumor Growth. Advances in Experimental Medicine and Biology, 2014, 772, 229-262.	0.8	155
76	Protection of innate immunity by C5aR antagonist in septic mice. FASEB Journal, 2002, 16, 1567-1574.	0.2	152
77	Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 628-633.	3.3	149
78	The C5a Receptor Impairs IL-12â€“Dependent Clearance of Porphyromonas gingivalis and Is Required for Induction of Periodontal Bone Loss. Journal of Immunology, 2011, 186, 869-877.	0.4	149
79	A structural basis for complement inhibition by Staphylococcus aureus. Nature Immunology, 2007, 8, 430-437.	7.0	148
80	Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology, 2000, 49, 133-148.	2.0	147
81	Expression and Function of C5a Receptor in Mouse Microvascular Endothelial Cells. Journal of Immunology, 2002, 169, 5962-5970.	0.4	145
82	Complement: more than a â€˜guardâ€™ against invading pathogens?. Trends in Immunology, 2002, 23, 485-491.	2.9	144
83	Diet-induced hepatocellular carcinoma in genetically predisposed mice. Human Molecular Genetics, 2009, 18, 2975-2988.	1.4	142
84	Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with ILâ€1Î². Journal of Cellular Biochemistry, 2011, 112, 2594-2605.	1.2	142
85	Multiple forms of complement C3 in trout that differ in binding to complement activators.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 8546-8551.	3.3	141
86	Increased C5a receptor expression in sepsis. Journal of Clinical Investigation, 2002, 110, 101-108.	3.9	141
87	Compstatin: A Complement Inhibitor on its Way to Clinical Application. Advances in Experimental Medicine and Biology, 2008, 632, 262-281.	0.8	139
88	Complement modulates the cutaneous microbiome and inflammatory milieu. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15061-15066.	3.3	138
89	Release of endogenous C3b inactivator from lymphocytes in response to triggering membrane receptors for beta 1H globulin.. Journal of Experimental Medicine, 1980, 152, 1625-1644.	4.2	137
90	Rational Engineering of a Minimized Immune Inhibitor with Unique Triple-Targeting Properties. Journal of Immunology, 2013, 190, 5712-5721.	0.4	137

#	Article	IF	Citations
91	Infection of human thymocytes by Epstein-Barr virus.. Journal of Experimental Medicine, 1991, 173, 971-980.	4.2	136
92	Complementing the Cancer-Immunity Cycle. Frontiers in Immunology, 2019, 10, 774.	2.2	136
93	Mesenchymal Stromal Cells Engage Complement and Complement Receptor Bearing Innate Effector Cells to Modulate Immune Responses. PLoS ONE, 2011, 6, e21703.	1.1	135
94	Compstatin Inhibits Complement and Cellular Activation in Whole Blood in Two Models of Extracorporeal Circulation. Blood, 1998, 92, 1661-1667.	0.6	133
95	Expression of Complement 3 and Complement 5 in Newt Limb and Lens Regeneration. Journal of Immunology, 2003, 170, 2331-2339.	0.4	130
96	New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology, 2013, 218, 496-505.	0.8	129
97	Complement activation triggered by chondroitin sulfate released by thrombin receptorâ€activated platelets. Journal of Thrombosis and Haemostasis, 2008, 6, 1413-1421.	1.9	127
98	The role of the complement system in metabolic organs and metabolic diseases. Seminars in Immunology, 2013, 25, 47-53.	2.7	126
99	C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. European Journal of Immunology, 2005, 35, 2496-2506.	1.6	125
100	A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF-Î²B inhibitor, IÎ²BÎ±. Hepatology, 2005, 42, 1148-1157.	3.6	125
101	Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood, 2010, 116, 631-639.	0.6	124
102	Role of Membrane Cofactor Protein (CD46) in Regulation of C4b and C3b Deposited on Cells. Journal of Immunology, 2002, 168, 6298-6304.	0.4	123
103	Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends in Immunology, 2009, 30, 286-292.	2.9	123
104	Regulators of complement activity mediate inhibitory mechanisms through a common C3bâ€binding mode. EMBO Journal, 2016, 35, 1133-1149.	3.5	123
105	Dissecting the instant bloodâ€mediated inflammatory reaction in islet xenotransplantation. Xenotransplantation, 2008, 15, 225-234.	1.6	121
106	Complement inhibition in cancer therapy. Seminars in Immunology, 2013, 25, 54-64.	2.7	121
107	Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist. Journal of Neuroimmunology, 2004, 155, 55-63.	1.1	119
108	Human genetic deficiencies reveal the roles of complement in the inflammatory network: Lessons from nature. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15861-15866.	3.3	119

#	Article	IF	Citations
109	Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition?. Trends in Immunology, 2010, 31, 32-38.	2.9	119
110	Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood, 2017, 129, 970-980.	0.6	119
111	Phylogenetic aspects of the complement system. Developmental and Comparative Immunology, 2001, 25, 745-762.	1.0	118
112	Ceruloplasmin/Hephaestin Knockout Mice Model Morphologic and Molecular Features of AMD. , 2008, 49, 2728.		117
113	Localization of the complement-component-C3b-binding site and the cofactor activity for factor I in the 38kDa tryptic fragment of factor H. Biochemical Journal, 1984, 224, 389-398.	1.7	116
114	Structure of Compstatin in Complex with Complement Component C3c Reveals a New Mechanism of Complement Inhibition. Journal of Biological Chemistry, 2007, 282, 29241-29247.	1.6	116
115	Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology, 2004, 325, 425-431.	1.1	115
116	C5a and TNF-Î± Up-Regulate the Expression of Tissue Factor in Intra-Alveolar Neutrophils of Patients with the Acute Respiratory Distress Syndrome. Journal of Immunology, 2008, 180, 7368-7375.	0.4	115
117	Crosstalk between the coagulation and complement systems in sepsis. Thrombosis Research, 2014, 133, S28-S31.	0.8	114
118	Complement and innate immunity. Immunopharmacology, 2000, 49, 187-198.	2.0	112
119	Complexity of complement activation in sepsis. Journal of Cellular and Molecular Medicine, 2008, 12, 2245-2254.	1.6	109
120	In Vivo Role of Complement-Interacting Domains of Herpes Simplex Virus Type 1 Glycoprotein Gc. Journal of Experimental Medicine, 1999, 190, 1637-1646.	4.2	108
121	Progress and Trends in Complement Therapeutics. Advances in Experimental Medicine and Biology, 2013, 735, 1-22.	0.8	107
122	Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses. Nature Structural and Molecular Biology, 2017, 24, 643-651.	3.6	106
123	Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies. European Journal of Immunology, 1988, 18, 1299-1302.	1.6	105
124	Binding Kinetics, Structure-Activity Relationship, and Biotransformation of the Complement Inhibitor Compstatin. Journal of Immunology, 2000, 165, 2491-2499.	0.4	105
125	Complement Component 3 Is Required for Optimal Expansion of CD8 T Cells During a Systemic Viral Infection. Journal of Immunology, 2003, 170, 788-794.	0.4	105
126	Porphyromonas gingivalisdisturbs hostâ€“commensal homeostasis by changing complement function. Journal of Oral Microbiology, 2017, 9, 1340085.	1.2	105

#	Article	IF	Citations
127	C3a Is Required for the Production of CXC Chemokines by Tubular Epithelial Cells after Renal Ishemia/Reperfusion. Journal of Immunology, 2007, 178, 1819-1828.	0.4	104
128	More than complementing Tolls: complementâ€“Tollâ€like receptor synergy and crosstalk in innate immunity and inflammation. Immunological Reviews, 2016, 274, 233-244.	2.8	104
129	Genetic and Pharmacologic Inhibition of Complement Impairs Endothelial Cell Function and Ablates Ovarian Cancer Neovascularization. Neoplasia, 2012, 14, 994-IN1.	2.3	103
130	Increased C5a receptor expression in sepsis. Journal of Clinical Investigation, 2002, 110, 101-108.	3.9	103
131	Hydrophobic Effect and Hydrogen Bonds Account for the Improved Activity of a Complement Inhibitor, Compstatin. Journal of Medicinal Chemistry, 2006, 49, 4616-4622.	2.9	100
132	Complement Component C3 Binds to Activated Normal Platelets without Preceding Proteolytic Activation and Promotes Binding to Complement Receptor 1. Journal of Immunology, 2010, 184, 2686-2692.	0.4	100
133	Local Complement-Targeted Intervention in Periodontitis: Proof-of-Concept Using a C5a Receptor (CD88) Antagonist. Journal of Immunology, 2012, 189, 5442-5448.	0.4	100
134	Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement.. Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 4235-4239.	3.3	98
135	G protein coupled receptor specificity for C3a and compound 48/80-induced degranulation in human mast cells: Roles of Mas-related genes MrgX1 and MrgX2. European Journal of Pharmacology, 2011, 668, 299-304.	1.7	98
136	Complement C5a Receptor Is Essential for the Optimal Generation of Antiviral CD8+ T Cell Responses. Journal of Immunology, 2004, 173, 2524-2529.	0.4	97
137	Complement and dysbiosis in periodontal disease. Immunobiology, 2012, 217, 1111-1116.	0.8	97
138	The Complement Anaphylatoxin C5a Receptor Contributes to Obese Adipose Tissue Inflammation and Insulin Resistance. Journal of Immunology, 2013, 191, 4367-4374.	0.4	97
139	Genetic and Intervention Studies Implicating Complement C3 as a Major Target for the Treatment of Periodontitis. Journal of Immunology, 2014, 192, 6020-6027.	0.4	97
140	Herpes Simplex Virus Type 1 Glycoprotein gC Mediates Immune Evasion In Vivo. Journal of Virology, 1998, 72, 8257-8263.	1.5	97
141	Recent developments in low molecular weight complement inhibitors. Molecular Immunology, 2009, 47, 185-195.	1.0	96
142	Neutrophil homeostasis and inflammation: novel paradigms from studying periodontitis. Journal of Leukocyte Biology, 2015, 98, 539-548.	1.5	96
143	Immune evasion properties of herpes simplex virus type 1 glycoprotein gC. Journal of Virology, 1996, 70, 4253-4260.	1.5	96
144	Diversity of the third form of complement, C3, in fish: functional characterization of five forms of C3 in the diploid fish Sparus aurata. Biochemical Journal, 1997, 326, 877-881.	1.7	95

#	Article	IF	Citations
145	The C-terminus of complement factor H is essential for host cell protection. Molecular Immunology, 2007, 44, 2697-2706.	1.0	95
146	Complement-Dependent Neutrophil Recruitment Is Critical for the Development of Elastase-Induced Abdominal Aortic Aneurysm. Circulation, 2009, 119, 1805-1813.	1.6	95
147	Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression. Cancer Research, 2018, 78, 143-156.	0.4	94
148	Structural and functional analysis of the complement component factor H with the use of different enzymes and monoclonal antibodies to factor H. Biochemical Journal, 1985, 232, 841-850.	1.7	93
149	New milestones ahead in complement-targeted therapy. Seminars in Immunology, 2016, 28, 208-222.	2.7	92
150	Herpes Simplex Virus Type 1 Evades the Effects of Antibody and Complement In Vivo. Journal of Virology, 2002, 76, 9232-9241.	1.5	91
151	The Regulation of Liver Cell Survival by Complement. Journal of Immunology, 2009, 182, 5412-5418.	0.4	91
152	Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation, 1999, 6, 52-65.	1.6	90
153	Complement in urochordates: cloning and characterization of two C3-like genes in the ascidian Ciona intestinalis. Immunogenetics, 2002, 53, 1055-1064.	1.2	90
154	Dysregulation of Stathmin, a Microtubule-Destabilizing Protein, and Up-Regulation of Hsp25, Hsp27, and the Antioxidant Peroxiredoxin 6 in a Mouse Model of Familial Amyotrophic Lateral Sclerosis. American Journal of Pathology, 2004, 165, 1701-1718.	1.9	90
155	PMX-53 as a Dual CD88 Antagonist and an Agonist for Mas-Related Gene 2 (MrgX2) in Human Mast Cells. Molecular Pharmacology, 2011, 79, 1005-1013.	1.0	89
156	Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria. Blood, 2015, 126, 891-894.	0.6	89
157	Solution structure of Compstatin, a potent complement inhibitor. Protein Science, 1998, 7, 619-627.	3.1	87
158	Murine visceral leishmaniasis: IgM and polyclonal Bâ€cell activation lead to disease exacerbation. European Journal of Immunology, 2010, 40, 1355-1368.	1.6	87
159	Integrated Computational and Experimental Approach for Lead Optimization and Design of Compstatin Variants with Improved Activity. Journal of the American Chemical Society, 2003, 125, 8422-8423.	6.6	85
160	Protection of Nonself Surfaces from Complement Attack by Factor H-Binding Peptides: Implications for Therapeutic Medicine. Journal of Immunology, 2011, 186, 4269-4277.	0.4	85
161	T cellâ€“derived interleukin (IL)-21 promotes brain injury following stroke in mice. Journal of Experimental Medicine, 2014, 211, 595-604.	4.2	85
162	Characterization of Ehp, a Secreted Complement Inhibitory Protein from Staphylococcus aureus. Journal of Biological Chemistry, 2007, 282, 30051-30061.	1.6	84

#	Article	IF	Citations
163	Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-CS antibodies. Molecular and Cellular Probes, 1987, 1, 141-149.	0.9	82
164	Expression of EBV/C3d receptors on T cells: biological significance. Trends in Immunology, 1993, 14, 56-59.	7.5	82
165	Liver inflammation and regeneration: Two distinct biological phenomena or parallel pathophysiologic processes?. Molecular Immunology, 2006, 43, 45-56.	1.0	82
166	Structural Change in Î±-Chymotrypsin Induced by Complexation with Î±1-Antichymotrypsin As Seen by Enhanced Sensitivity to Proteolysisâ€. Biochemistry, 1996, 35, 10608-10615.	1.2	81
167	Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. Molecular Immunology, 2003, 39, 557-566.	1.0	81
168	Complement anaphylatoxin C3a is a potent inducer of embryonic chick retina regeneration. Nature Communications, 2013, 4, 2312.	5.8	80
169	Hormonal regulation of complement components and receptors throughout the menstrual cycle. American Journal of Obstetrics and Gynecology, 1994, 170, 168-175.	0.7	78
170	Allosteric inhibition of complement function by a staphylococcal immune evasion protein. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17621-17626.	3.3	77
171	Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10948-10953.	3.3	77
172	Functional Relevance of the Anaphylatoxin Receptor C3aR for Platelet Function and Arterial Thrombus Formation Marks an Intersection Point Between Innate Immunity and Thrombosis. Circulation, 2018, 138, 1720-1735.	1.6	77
173	Cloning and structure of three rainbow trout C3 molecules: a plausible explanation for their functional diversity. Developmental and Comparative Immunology, 2001, 25, 11-24.	1.0	76
174	CiC3-1a-Mediated Chemotaxis in the Deuterostome InvertebrateCiona intestinalis(Urochordata). Journal of Immunology, 2003, 171, 5521-5528.	0.4	76
175	The Challenges and Promise of Complement Therapeutics for Ocular Diseases. Frontiers in Immunology, 2019, 10, 1007.	2.2	76
176	Structural analysis of the asparagine-linked oligosaccharides of human complement component C3. Biochemical Journal, 1986, 233, 613-616.	1.7	75
177	Synergistic neuroprotective effects of C3a and C5a receptor blockade following intracerebral hemorrhage. Brain Research, 2009, 1298, 171-177.	1.1	75
178	Role of complement in hostâ€“microbe homeostasis of the periodontium. Seminars in Immunology, 2013, 25, 65-72.	2.7	75
179	Electrostatic Modeling Predicts the Activities of Orthopoxvirus Complement Control Proteins. Journal of Immunology, 2005, 174, 2143-2151.	0.4	73
180	Acute Antibody-Mediated Complement Activation Mediates Lysis of Pancreatic Islets Cells and May Cause Tissue Loss in Clinical Islet Transplantation. Transplantation, 2008, 85, 1193-1199.	0.5	73

#	Article	IF	Citations
181	C3a Receptor Antagonist Attenuates Brain Injury after Intracerebral Hemorrhage. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 98-107.	2.4	73
182	Kinetic Analysis of the Interactions of Complement Receptor 2 (CR2, CD21) with Its Ligands C3d, iC3b, and the EBV Glycoprotein gp350/220. Journal of Immunology, 2001, 167, 1490-1499.	0.4	72
183	Complement-triggered pathways orchestrate regenerative responses throughout phylogenesis. Seminars in Immunology, 2013, 25, 29-38.	2.7	72
184	Isolation of lymphocyte membrane complement receptor type two (the C3d receptor) and preparation of receptor-specific antibody.. Proceedings of the National Academy of Sciences of the United States of America, 1981, 78, 1828-1832.	3.3	71
185	Synthesis and Activity of Thioether-Containing Analogues of the Complement Inhibitor Compstatin. ACS Chemical Biology, 2011, 6, 753-760.	1.6	70
186	Minimum length of an idiotypic peptide and a model for its binding to a major histocompatibility complex class II molecule.. EMBO Journal, 1989, 8, 1947-1952.	3.5	69
187	Inhibition of Heparin/Protamine Complex-Induced Complement Activation by Compstatin in Baboons. Clinical Immunology, 2000, 96, 212-221.	1.4	68
188	Kinetic Analysis of Glycoprotein C of Herpes Simplex Virus Types 1 and 2 Binding to Heparin, Heparan Sulfate, and Complement Component C3b. Virology, 2002, 294, 324-332.	1.1	68
189	Effect of complement inhibition and heparin coating on artificial surfaceâ€“induced leukocyte and platelet activation. Annals of Thoracic Surgery, 2004, 77, 932-941.	0.7	68
190	Design and NMR Characterization of Active Analogues of Compstatin Containing Non-Natural Amino Acids. Journal of Medicinal Chemistry, 2005, 48, 274-286.	2.9	68
191	Structural and Antigenic Analysis of a Truncated Form of the Herpes Simplex Virus Glycoprotein gH-gL Complex. Journal of Virology, 1998, 72, 6092-6103.	1.5	68
192	Complementary Tolls in the periodontium: how periodontal bacteria modify complement and Toll-like receptor responses to prevail in the host. Periodontology 2000, 2010, 52, 141-162.	6.3	66
193	Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques. Molecular Therapy, 2015, 23, 1066-1076.	3.7	65
194	Pericytes and immune cells contribute to complement activation in tubulointerstitial fibrosis. American Journal of Physiology - Renal Physiology, 2017, 312, F516-F532.	1.3	64
195	Phylogeny of the third component of complement, C3: Analysis of the conservation of human CR1, CR2, H, and B binding sites, concanavalin A binding sites, and thiolester bond in the C3 from different species. Developmental and Comparative Immunology, 1992, 16, 63-76.	1.0	63
196	Hormonal regulation of complement components and receptors throughout the menstrual cycle. American Journal of Obstetrics and Gynecology, 1994, 170, 168-175.	0.7	63
197	A Molecular Insight into Complement Evasion by the Staphylococcal Complement Inhibitor Protein Family. Journal of Immunology, 2009, 183, 2565-2574.	0.4	63
198	Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Molecular Immunology, 2011, 48, 481-489.	1.0	62

#	Article	IF	Citations
199	Characterization of the lymphocyte membrane receptor for factor H (Î²1H- globulin) with an antibody to anti-factor H idiotype. Journal of Experimental Medicine, 1982, 155, 1400-1411.	4.2	61
200	The Interaction of Glycoprotein C of Herpes Simplex Virus Types 1 and 2 with the Alternative Complement Pathway. Virology, 1994, 203, 299-312.	1.1	61
201	The Complement System Is Critical in Maintaining Retinal Integrity during Aging. Frontiers in Aging Neuroscience, 2018, 10, 15.	1.7	61
202	Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Open Reading Frame 4 Protein (Kaposica) Is a Functional Homolog of Complement Control Proteins. Journal of Virology, 2003, 77, 3878-3881.	1.5	60
203	The Anaphylatoxin Receptor C5aR Is Present During Fracture Healing in Rats and Mediates Osteoblast Migration In Vitro. Journal of Trauma, 2011, 71, 952-960.	2.3	60
204	Applying complement therapeutics to rare diseases. Clinical Immunology, 2015, 161, 225-240.	1.4	60
205	Complement-Dependent Mechanisms and Interventions in Periodontal Disease. Frontiers in Immunology, 2019, 10, 406.	2.2	60
206	Suppression of Drusen Formation by Compstatin, a Peptide Inhibitor of Complement C3 activation, on Cynomolgus Monkey with Early-Onset Macular Degeneration. Advances in Experimental Medicine and Biology, 2010, 703, 127-135.	0.8	59
207	Acquired C1 inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies.. Journal of Clinical Investigation, 1989, 83, 1794-1799.	3.9	59
208	Complement Deficiency Promotes Cutaneous Wound Healing in Mice. Journal of Immunology, 2015, 194, 1285-1291.	0.4	58
209	Inhibition of the alternative complement pathway preserves photoreceptors after retinal injury. Science Translational Medicine, 2015, 7, 297ra116.	5.8	58
210	Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. Immunobiology, 2015, 220, 476-482.	0.8	58
211	Complement C5a Functions as a Master Switch for the pH Balance in Neutrophils Exerting Fundamental Immunometabolic Effects. Journal of Immunology, 2017, 198, 4846-4854.	0.4	58
212	Complement C5aâ€Induced Changes in Neutrophil Morphology During Inflammation. Scandinavian Journal of Immunology, 2017, 86, 143-155.	1.3	58
213	Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays. Molecular Immunology, 2004, 40, 1213-1221.	1.0	57
214	Novel Mechanism of Antibody-Independent Complement Neutralization of Herpes Simplex Virus Type 1. Journal of Immunology, 2000, 165, 4528-4536.	0.4	56
215	Design of Peptide Analogues with Improved Activity Using a Novel de Novo Protein Design Approach. Industrial & Engineering Chemistry Research, 2004, 43, 3817-3826.	1.8	56
216	Structural Studies in Solution of the Recombinant N-Terminal Pair of Short Consensus/Complement Repeat Domains of Complement Receptor Type 2 (CR2/CD21) and Interactions with Its Ligand C3dg. Biochemistry, 2001, 40, 5931-5941.	1.2	55

#	Article	IF	Citations
217	Inhibition of preâ€existing natural periodontitis in nonâ€human primates by a locally administered peptide inhibitor of complement C3. Journal of Clinical Periodontology, 2016, 43, 238-249.	2.3	55
218	Cloning and purification of the rainbow trout fifth component of complement (C5). Developmental and Comparative Immunology, 2001, 25, 419-430.	1.0	54
219	Cutting Edge: Members of the Staphylococcus aureus Extracellular Fibrinogen-Binding Protein Family Inhibit the Interaction of C3d with Complement Receptor 2. Journal of Immunology, 2008, 181, 7463-7467.	0.4	54
220	The alternative complement pathway regulates pathological angiogenesis in the retina. FASEB Journal, 2014, 28, 3171-3182.	0.2	54
221	The Evolution and Appearance of C3 Duplications in Fish Originate an Exclusive Teleost c3 Gene Form with Anti-Inflammatory Activity. PLoS ONE, 2014, 9, e99673.	1.1	54
222	Complement: Structure, Functions, Evolution, and Viral Molecular Mimicry. Immunologic Research, 2003, 27, 367-386.	1.3	53
223	C5a causes limited, polymorphonuclear cell-independent, mesenteric ischemia/reperfusion-induced injuryâ†,â†â†. Clinical Immunology, 2003, 108, 263-273.	1.4	53
224	Complement Involvement in Periodontitis: Molecular Mechanisms and Rational Therapeutic Approaches. Advances in Experimental Medicine and Biology, 2015, 865, 57-74.	0.8	53
225	Complement Activation Is Critical to Airway Hyperresponsiveness after Acute Ozone Exposure. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 726-732.	2.5	52
226	A Complementâ€“IL-4 Regulatory Circuit Controls Liver Regeneration. Journal of Immunology, 2012, 188, 641-648.	0.4	52
227	Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.. Journal of Clinical Investigation, 1985, 76, 1418-1426.	3.9	52
228	Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement. Molecular Immunology, 2007, 44, 1819-1826.	1.0	51
229	The Extracellular Adherence Protein from Staphylococcus aureus Inhibits the Classical and Lectin Pathways of Complement by Blocking Formation of the C3 Proconvertase. Journal of Immunology, 2014, 193, 6161-6171.	0.4	51
230	Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. Cancer Letters, 2022, 529, 70-84.	3.2	51
231	The Structural Basis of Compstatin Activity Examined by Structure-Function-based Design of Peptide Analogs and NMR. Journal of Biological Chemistry, 2002, 277, 14942-14953.	1.6	50
232	Unwelcome Complement. Cancer Research, 2009, 69, 6367-6370.	0.4	50
233	C5a Receptor-Dependent Cell Activation by Physiological Concentrations of Desarginated C5a: Insights from a Novel Label-Free Cellular Assay. Journal of Immunology, 2012, 189, 4797-4805.	0.4	50
234	Autoregulation of thromboinflammation on biomaterial surfaces by a multicomponent therapeutic coating. Biomaterials, 2013, 34, 985-994.	5.7	50

#	Article	IF	Citations
235	Epitope Mapping Using the X-Ray Crystallographic Structure of Complement Receptor Type 2 (CR2)/CD21: Identification of a Highly Inhibitory Monoclonal Antibody That Directly Recognizes the CR2-C3d Interface. Journal of Immunology, 2001, 167, 5758-5766.	0.4	49
236	Structural aspects and design of low-molecular-mass complement inhibitors. Biochemical Society Transactions, 2002, 30, 1026-1036.	1.6	49
237	Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. Immunobiology, 2015, 220, 993-998.	0.8	49
238	The Electrostatic Nature of C3d-Complement Receptor 2 Association. Journal of Immunology, 2004, 172, 7537-7547.	0.4	48
239	A Protective Role for the Fifth Complement Component (C5) in Allergic Airway Disease. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 852-857.	2.5	48
240	Structureâ€kinetic relationship analysis of the therapeutic complement inhibitor compstatin. Journal of Molecular Recognition, 2009, 22, 495-505.	1.1	48
241	Blood proteinâ€polymer adsorption: Implications for understanding complementâ€mediated hemoincompatibility. Journal of Biomedical Materials Research - Part A, 2011, 97A, 74-84.	2.1	48
242	Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy. OncoImmunology, 2017, 6, e1326442.	2.1	48
243	Mouse genetics and proteomic analyses demonstrate a critical role for complement in a model of DHRD/ML, an inherited macular degeneration. Human Molecular Genetics, 2014, 23, 52-68.	1.4	47
244	Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction. Frontiers in Immunology, 2019, 10, 543.	2.2	47
245	Phase IIa clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation. Journal of Clinical Investigation, 2021, 131, .	3.9	47
246	Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.6	45
247	Does complement play a role in bone development and regeneration?. Immunobiology, 2013, 218, 1-9.	0.8	45
248	Ancient Origin of the Complement System: Emerging Invertebrate Models. , 2007, 598, 372-388.		45
249	Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Blood, 2002, 100, 4544-4549.	0.6	44
250	Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application. Seminars in Immunology, 2016, 28, 285-291.	2.7	44
251	Interlaboratory Comparison of Hydrogenâ€“Deuterium Exchange Mass Spectrometry Measurements of the Fab Fragment of NISTmAb. Analytical Chemistry, 2019, 91, 7336-7345.	3.2	44
252	Cell Surface Proteins Reacting with Activated Complement Components. Complement and Inflammation, 1989, 6, 142-165.	0.8	43

#	Article	IF	Citations
253	Conservation of structural and functional domains in complement component C3 of Xenopus and mammals.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 1323-1327.	3.3	43
254	Partial hepatectomy induced liver proteome changes in mice. Proteomics, 2005, 5, 318-325.	1.3	43
255	Pathogenic Microbes and Community Service Through Manipulation of Innate Immunity. Advances in Experimental Medicine and Biology, 2012, 946, 69-85.	0.8	43
256	Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Review of Hematology, 2014, 7, 583-598.	1.0	43
257	Novel biological networks modulated by complement. Clinical Immunology, 2005, 115, 225-235.	1.4	42
258	C3 Promotes Expansion of CD8+ and CD4+ T Cells in a Listeria monocytogenes Infection. Journal of Immunology, 2009, 183, 2921-2931.	0.4	42
259	The Chemistry and Biology of C3, C4 and C5. , 1998, , 83-118.		42
260	Contribution of Chondroitin Sulfate A to the Binding of Complement Proteins to Activated Platelets. PLoS ONE, 2010, 5, e12889.	1.1	42
261	C5aRâ€antagonist significantly reduces the deleterious effect of a blunt chest trauma on fracture healing. Journal of Orthopaedic Research, 2012, 30, 581-586.	1.2	41
262	Therapeutic control of complement activation at the level of the central component C3. Immunobiology, 2016, 221, 740-746.	0.8	41
263	Segment spanning residues 727-768 of the complement C3 sequence contains a neoantigenic site and accommodates the binding of CR1, factor H, and factor B. Biochemistry, 1992, 31, 1787-1794.	1.2	40
264	The artificial surfaceâ€induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent. Journal of Biomedical Materials Research - Part A, 2008, 87A, 129-135.	2.1	40
265	Ornithodoros moubata Complement Inhibitor Is an Equally Effective C5 Inhibitor in Pigs and Humans. Journal of Immunology, 2011, 187, 4913-4919.	0.4	40
266	Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles. Biomaterials, 2014, 35, 3688-3696.	5.7	40
267	Peptides of myelin basic protein stimulate T lymphocytes from patients with multiple sclerosis. Journal of Neuroimmunology, 1989, 22, 23-30.	1.1	39
268	Studies of Structure-Activity Relations of Complement Inhibitor Compstatin. Journal of Immunology, 2003, 171, 1881-1890.	0.4	39
269	Molecular Basis for Complement Recognition and Inhibition Determined by Crystallographic Studies of the Staphylococcal Complement Inhibitor (SCIN) Bound to C3c and C3b. Journal of Molecular Biology, 2010, 402, 17-29.	2.0	39
270	Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. Immunobiology, 2012, 217, 1097-1105.	0.8	39

#	Article	IF	Citations
271	Erythrocytes identify complement activation in patients with COVID-19. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L485-L489.	1.3	39
272	Accumulation of viruslike particles in a yeast mutant lacking a mitochondrial pore protein.. Molecular and Cellular Biology, 1989, 9, 1100-1108.	1.1	38
273	Stages of Meningococcal Sepsis Simulated In Vitro, with Emphasis on Complement and Toll-Like Receptor Activation. Infection and Immunity, 2008, 76, 4183-4189.	1.0	38
274	The Role of Properdin in Zymosan- and Escherichia coli-Induced Complement Activation. Journal of Immunology, 2012, 189, 2606-2613.	0.4	38
275	Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18. Thrombosis and Haemostasis, 2015, 114, 1207-1217.	1.8	38
276	High-Fat Diet-Induced Complement Activation Mediates Intestinal Inflammation and Neoplasia, Independent of Obesity. Molecular Cancer Research, 2016, 14, 953-965.	1.5	38
277	Safety profile after prolonged C3 inhibition. Clinical Immunology, 2018, 197, 96-106.	1.4	38
278	First Identification of a Chemotactic Receptor in an Invertebrate Species: Structural and Functional Characterization of Ciona intestinalis C3a Receptor. Journal of Immunology, 2006, 177, 4132-4140.	0.4	37
279	Complement Activation by CpG in a Human Whole Blood Loop System: Mechanisms and Immunomodulatory Effects. Journal of Immunology, 2009, 183, 6724-6732.	0.4	37
280	Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor Hâ€“like Protein 1 Reveal Functional Determinants of Complement Regulation. Journal of Immunology, 2016, 196, 866-876.	0.4	37
281	Therapeutic targeting of the complement system. Nature Reviews Drug Discovery, 2019, , .	21.5	37
282	Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions. Progress in Retinal and Eye Research, 2021, 83, 100936.	7.3	37
283	Contribution of the Innate Immune System to Autoimmune Diabetes: A Role for the CR1/CR2 Complement Receptors. Cellular Immunology, 1999, 195, 75-79.	1.4	36
284	The three HveA receptor ligands, gD, LT-Î± and LIGHT bind to distinct sites on HveA. Molecular Immunology, 2000, 37, 665-673.	1.0	36
285	An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood. Gene Therapy, 2010, 17, 752-762.	2.3	36
286	Complement inhibition decreases early fibrogenic events in the lung of septic baboons. Journal of Cellular and Molecular Medicine, 2015, 19, 2549-2563.	1.6	36
287	Complement therapeutics in inflammatory diseases: promising drug candidates for C3â€targeted intervention. Molecular Oral Microbiology, 2016, 31, 3-17.	1.3	36
288	Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of age-related macular degeneration by restoring lysosomal function. Stem Cells Translational Medicine, 2020, 9, 1585-1603.	1.6	36

#	Article	IF	Citations
289	Inhibition of biomaterialâ€induced complement activation attenuates the inflammatory host response to implantation. FASEB Journal, 2013, 27, 2768-2776.	0.2	35
290	The induction of cytokines by polycation containing microspheres by a complement dependent mechanism. Biomaterials, 2013, 34, 621-630.	5.7	35
291	Properdin-Mediated C5a Production Enhances Stable Binding of Platelets to Granulocytes in Human Whole Blood. Journal of Immunology, 2016, 196, 4671-4680.	0.4	35
292	Complement receptors C5aR1 and C5aR2 act differentially during the early immune response after bone fracture but are similarly involved in bone repair. Scientific Reports, 2017, 7, 14061.	1.6	35
293	Molecular cloning of the Î² subunit of complement component eight of rainbow trout. Developmental and Comparative Immunology, 2003, 27, 167-174.	1.0	34
294	Improvement of the anti-C3 activity of compstatin using rational and combinatorial approaches. Biochemical Society Transactions, 2004, 32, 28-32.	1.6	34
295	Electrostatic contributions drive the interaction between Staphylococcus aureus protein Efbâ€€ and its complement target C3d. Protein Science, 2008, 17, 1894-1906.	3.1	34
296	Immune competence of the Ciona intestinalis pharynx: Complement system-mediated activity. Fish and Shellfish Immunology, 2012, 33, 946-952.	1.6	34
297	Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule. Haematologica, 2019, 104, 919-928.	1.7	34
298	Protective Effects of the Complement Inhibitor Compstatin CP40 in Hemorrhagic Shock. Shock, 2019, 51, 78-87.	1.0	34
299	Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression. Nature Cancer, 2021, 2, 218-232.	5.7	34
300	C5L2 receptor disruption enhances the development of diet-induced insulin resistance in mice. Immunobiology, 2013, 218, 127-133.	0.8	33
301	Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates. Molecular Therapy - Methods and Clinical Development, 2017, 6, 207-215.	1.8	33
302	Mapping of the properdin-binding site in the third component of complement. Biochemical Journal, 1984, 217, 323-326.	1.7	32
303	Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Seminars in Hematology, 2018, 55, 167-175.	1.8	32
304	Neoantigens in complement component C3 as detected by monoclonal antibodies. Mapping of the recognized epitopes by synthetic peptides. Biochemical Journal, 1990, 268, 55-61.	1.7	31
305	Advances in Understanding the Structure, Function, and Mechanism of the SCIN and Efb Families of Staphylococcal Immune Evasion Proteins. Advances in Experimental Medicine and Biology, 2012, 946, 113-133.	0.8	31
306	Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. Trends in Immunology, 2017, 38, 383-394.	2.9	31

#	Article	IF	Citations
307	Cholesterol Crystals Induce Coagulation Activation through Complement-Dependent Expression of Monocytic Tissue Factor. Journal of Immunology, 2019, 203, 853-863.	0.4	31
308	Compstatins: the dawn of clinical C3-targeted complement inhibition. Trends in Pharmacological Sciences, 2022, 43, 629-640.	4.0	31
309	Differential Effect of Heparin Coating and Complement Inhibition on Artificial Surface-Induced Eicosanoid Production. Annals of Thoracic Surgery, 2005, 79, 917-923.	0.7	30
310	Acute Lung Injury and Fibrosis in a Baboon Model of Escherichia coli Sepsis. American Journal of Respiratory Cell and Molecular Biology, 2014, 50, 439-450.	1.4	30
311	The third component ofXenopus complement: cDNA cloning, structural and functional analysis, and evidence for an alternate C3 transcript. European Journal of Immunology, 1995, 25, 572-578.	1.6	29
312	Physical methods for structure, dynamics and binding in immunological research. Trends in Immunology, 2004, 25, 700-707.	2.9	29
313	Preclinical evaluation of innate immunity to baculovirus gene therapy vectors in whole human blood. Molecular Immunology, 2009, 46, 2911-2917.	1.0	29
314	C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates. Nature Communications, 2021, 12, 5456.	5.8	29
315	In vivo changes in complement induced with peptidoglycan-polysaccharide polymers from streptococcal cell walls. Infection and Immunity, 1982, 35, 377-380.	1.0	29
316	Complement Component C5a Is Integral to the Febrile Response of Mice to Lipopolysaccharide. NeuroImmunoModulation, 2005, 12, 67-80.	0.9	28
317	Cytokine Secretion Depends on GalÎ±(1,3)Gal Expression in a Pig-to-Human Whole Blood Model. Journal of Immunology, 2008, 180, 6346-6353.	0.4	28
318	Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. Immunobiology, 2016, 221, 503-511.	0.8	28
319	Coarse-Grained Conformational Sampling of Protein Structure Improves the Fit to Experimental Hydrogen-Exchange Data. Frontiers in Molecular Biosciences, 2017, 4, 13.	1.6	28
320	Synthetic small-molecule complement inhibitors. Current Opinion in Investigational Drugs, 2004, 5, 1164-73.	2.3	28
321	Structure, functions, and evolution of the third complement component and viral molecular mimicry. Immunologic Research, 1998, 17, 109-121.	1.3	27
322	Restoration of Complement-Enhanced Neutralization of Vaccinia Virus Virions by Novel Monoclonal Antibodies Raised against the Vaccinia Virus Complement Control Protein. Journal of Virology, 2003, 77, 8256-8262.	1.5	27
323	Iron oxide nanoparticles induce cytokine secretion in a complement-dependent manner in a human whole blood model. International Journal of Nanomedicine, 2017, Volume 12, 3927-3940.	3.3	27
324	C3-targeted therapy in periodontal disease: moving closer to the clinic. Trends in Immunology, 2021, 42, 856-864.	2.9	27

#	Article	IF	Citations
325	Isolation of rat IgM to IgG hybridoma isotype switch variants and analysis of the efficiency of rat Ig in complement activation. European Journal of Immunology, 1989, 19, 131-135.	1.6	26
326	Hormonal Regulation of Complement Factor B in Human Endometrium. American Journal of Reproductive Immunology, 1993, 30, 63-67.	1.2	26
327	Prolongation of ex vivoâ€“perfused pig xenograft survival by the complement inhibitor compstatin. Transplantation Proceedings, 1999, 31, 934-935.	0.3	26
328	A Functional C5a Anaphylatoxin Receptor in a Teleost Species. Journal of Immunology, 2004, 172, 349-355.	0.4	26
329	Solvent Accessibility of Native and Hydrolyzed Human Complement Protein 3 Analyzed by Hydrogen/Deuterium Exchange and Mass Spectrometry. Journal of Immunology, 2005, 174, 3469-3474.	0.4	26
330	ciCD94-1, an ascidian multipurpose C-type lectin-like receptor expressed in Ciona intestinalis hemocytes and larval neural structures. Differentiation, 2008, 76, 267-282.	1.0	26
331	Diversity in the C3b Convertase Contact Residues and Tertiary Structures of the Staphylococcal Complement Inhibitor (SCIN) Protein Family. Journal of Biological Chemistry, 2012, 287, 628-640.	1.6	26
332	CMAP: Complement Map Database. Bioinformatics, 2013, 29, 1832-1833.	1.8	26
333	Factor Hâ€“IgG Chimeric Proteins as a Therapeutic Approach against the Gram-Positive Bacterial Pathogen Streptococcus pyogenes. Journal of Immunology, 2017, 199, 3828-3839.	0.4	26
334	Interaction between Epstein-Barr virus and a T cell line (HSB-2) via a receptor phenotypically distinct from complement receptor type 2. European Journal of Immunology, 1992, 22, 1123-1131.	1.6	25
335	Compstatin inhibits complement activation by binding to the Î²-chain of complement factor 3. Molecular Immunology, 2006, 43, 2023-2029.	1.0	25
336	Regulation of Instant Blood Mediated Inflammatory Reaction (IBMIR) in Pancreatic Islet Xeno-Transplantation: Points for Therapeutic Interventions. Advances in Experimental Medicine and Biology, 2015, 865, 171-188.	0.8	25
337	Is complement the culprit behind COVID-19 vaccine-related adverse reactions?. Journal of Clinical Investigation, 2021, 131, .	3.9	25
338	Thermodynamic Studies on the Interaction of the Third Complement Component and Its Inhibitor, Compstatin. Journal of Biological Chemistry, 2004, 279, 54987-54995.	1.6	24
339	Complement: An Inflammatory Pathway Fulfilling Multiple Roles at the Interface of Innate Immunity and Development. Inflammation and Allergy: Drug Targets, 2005, 4, 125-127.	3.1	24
340	Immune Evasion ofMoraxella catarrhalisInvolves Ubiquitous Surface Protein A-Dependent C3d Binding. Journal of Immunology, 2011, 186, 3120-3129.	0.4	24
341	Induction of Complement C3a Receptor Responses by Kallikrein-Related Peptidase 14. Journal of Immunology, 2013, 191, 3858-3866.	0.4	24
342	Gingival Exudatome Dynamics Implicate Inhibition of the Alternative Complement Pathway in the Protective Action of the C3 Inhibitor Cp40 in Nonhuman Primate Periodontitis. Journal of Proteome Research, 2018, 17, 3153-3175.	1.8	24

#	Article	IF	Citations
343	HUMAN SERUM-INDUCED EXPRESSION OF E-SELECTIN ON PORCINE AORTIC ENDOTHELIAL CELLS IN VITRO IS TOTALLY COMPLEMENT MEDIATED1. Transplantation, 2001, 72, 1967-1973.	0.5	24
344	The multifunctional role of C3: Structural analysis of its interactions with physiological ligands. Molecular Immunology, 1986, 23, 1237-1242.	1.0	23
345	The Central Segment of Herpes Simplex Virus Type 1 Glycoprotein C (gC) Is Not Involved in C3b Binding: Demonstration by Using Monoclonal Antibodies and Recombinant gC Expressed in Escherichia coli. Journal of General Virology, 1989, 70, 1571-1578.	1.3	23
346	A role for Lys-His-Gly-NH2 in avian and murine B cell development. Cellular Immunology, 1989, 122, 319-328.	1.4	23
347	Conformational interconversion in compstatin probed with molecular dynamics simulations. Proteins: Structure, Function and Bioinformatics, 2003, 53, 130-141.	1.5	23
348	Absence of Mannose-Binding Lectin Prevents Hyperglycemic Cardiovascular Complications. American Journal of Pathology, 2012, 180, 104-112.	1.9	23
349	Rare Loss-of-Function Mutation in Complement Component C3 Provides Insight into Molecular and Pathophysiological Determinants of Complement Activity. Journal of Immunology, 2015, 194, 3305-3316.	0.4	23
350	Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia. Clinical Immunology, 2016, 171, 32-35.	1.4	23
351	New Analogs of the Complement C3 Inhibitor Compstatin with Increased Solubility and Improved Pharmacokinetic Profile. Journal of Medicinal Chemistry, 2018, 61, 6153-6162.	2.9	23
352	Complement mediates binding and procoagulant effects of ultralarge HIT immune complexes. Blood, 2021, 138, 2106-2116.	0.6	23
353	Complement component C3: A structural perspective and potential therapeutic implications. Seminars in Immunology, 2022, 59, 101627.	2.7	23
354	Conformational differences between surface-bound and fluid-phase complement-component-C3 fragments. Epitope mapping by cDNA expression. Biochemical Journal, 1992, 282, 715-721.	1.7	22
355	Liver Regeneration: A Link to Inflammation through Complement. , 2006, 586, 17-34.		22
356	Complement Component C5a Mediates Hemorrhage-Induced Intestinal Damage. Journal of Surgical Research, 2008, 150, 196-203.	0.8	22
357	C1-inhibitor efficiently inhibitsEscherichiaâ€‰coli-induced tissue factor mRNA up-regulation, monocyte tissue factor expression and coagulation activation in human whole blood. Clinical and Experimental Immunology, 2013, 173, 217-229.	1.1	22
358	Systems Analysis of the Complement-Induced Priming Phase of Liver Regeneration. Journal of Immunology, 2016, 197, 2500-2508.	0.4	22
359	Control of the collective migration of enteric neural crest cells by the Complement anaphylatoxin C3a and N-cadherin. Developmental Biology, 2016, 414, 85-99.	0.9	22
360	Structural Implications for the Formation and Function of the Complement Effector Protein iC3b. Journal of Immunology, 2017, 198, 3326-3335.	0.4	21

#	Article	IF	Citations
361	Lymphocyte mitogenesis induced by monoclonal antibodies to the T3 complex. Differential modulation by human IgG. Cellular Immunology, 1984, 89, 66-74.	1.4	20
362	DAF/Crry double deficiency in mice exacerbates nephrotoxic serum-induced proteinuria despite markedly reduced systemic complement activity. Molecular Immunology, 2007, 44, 139-146.	1.0	20
363	Solution insights into the structure of the Efb/C3 complement inhibitory complex as revealed by lysine acetylation and mass spectrometry. Journal of the American Society for Mass Spectrometry, 2008, 19, 55-65.	1.2	20
364	In Vivo Significance of ITK-SLP-76 Interaction in Cytokine Production. Molecular and Cellular Biology, 2010, 30, 3596-3609.	1.1	20
365	Neisseria meningitidis and Escherichia coli are protected from leukocyte phagocytosis by binding to erythrocyte complement receptor 1 in human blood. Molecular Immunology, 2011, 48, 2159-2169.	1.0	20
366	The Role of Third Complement Component (C3) in Homing of Hematopoietic Stem/Progenitor Cells into Bone Marrow. , 2006, 586, 35-51.		20
367	The Effects of Selective Complement and CD14 Inhibition on the E. coli-Induced Tissue Factor mRNA Upregulation, Monocyte Tissue Factor Expression, and Tissue Factor Functional Activity in Human Whole Blood. Advances in Experimental Medicine and Biology, 2013, 735, 123-136.	0.8	20
368	Pathogenesis of B-Cell Superantigen-Induced Immune Complex-Mediated Inflammation. Infection and Immunity, 2006, 74, 1196-1203.	1.0	19
369	Dynamic structural changes during complement C3 activation analyzed by hydrogen/deuterium exchange mass spectrometry. Molecular Immunology, 2008, 45, 3142-3151.	1.0	19
370	Expression of compstatin in Escherichia coli: Incorporation of unnatural amino acids enhances its activity. Protein Expression and Purification, 2006, 47, 289-295.	0.6	18
371	Early post-operative measurement of cytokine plasma levels combined with pre-operative bilirubin levels identify high-risk patients after liver resection. International Journal of Molecular Medicine, 2011, 27, 447-54.	1.8	18
372	A Murine Rp1 Missense Mutation Causes Protein Mislocalization and Slowly Progressive Photoreceptor Degeneration. American Journal of Pathology, 2014, 184, 2721-2729.	1.9	18
373	Serum amyloid P component is an essential element of resistance against Aspergillus fumigatus. Nature Communications, 2021, 12, 3739.	5.8	18
374	Real-time label-free detection of complement activation products in human serum by white light reflectance spectroscopy. Biosensors and Bioelectronics, 2009, 24, 3359-3364.	5.3	17
375	Artificial Surface-Induced Inflammation Relies on Complement Factor 5: Proof From a Deficient Person. Annals of Thoracic Surgery, 2011, 91, 527-533.	0.7	17
376	Post challenge inhibition of C3 and CD14 attenuates Escherichia coli-induced inflammation in human whole blood. Innate Immunity, 2014, 20, 68-77.	1.1	17
377	Complement Inhibition in a Xenogeneic Model of Interactions Between Human Whole Blood and Porcine Endothelium. Hormone and Metabolic Research, 2015, 47, 36-42.	0.7	17
378	Differential capacity for complement receptorâ€mediated immune evasion by Porphyromonas gingivalis depending on the type of innate leukocyte. Molecular Oral Microbiology, 2017, 32, 154-165.	1.3	17

#	Article	IF	Citations
379	Alginate microbeads are coagulation compatible, while alginate microcapsules activate coagulation secondary to complement or directly through FXII. Acta Biomaterialia, 2017, 58, 158-167.	4.1	17
380	Complement C3 inhibition by compstatin Cp40 prevents intra- and extravascular hemolysis of red blood cells. Haematologica, 2020, 105, e57-e60.	1.7	17
381	Complement-Targeted Therapeutics in Periodontitis. Advances in Experimental Medicine and Biology, 2013, 735, 197-206.	0.8	17
382	A Structurally Dynamic N-terminal Helix Is a Key Functional Determinant in Staphylococcal Complement Inhibitor (SCIN) Proteins. Journal of Biological Chemistry, 2013, 288, 2870-2881.	1.6	16
383	Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates. Clinical Immunology, 2020, 214, 108391.	1.4	16
384	CD14 inhibition improves survival and attenuates thromboâ€inflammation and cardiopulmonary dysfunction in a baboon model of Escherichia coli sepsis. Journal of Thrombosis and Haemostasis, 2021, 19, 429-443.	1.9	16
385	Exploring the Complement Interaction Network Using Surface Plasmon Resonance. , 2007, 598, 260-278.		16
386	Complement activation on neutrophils initiates endothelial adhesion and extravasation. Molecular Immunology, 2019, 114, 629-642.	1.0	15
387	Soluble collectin-12 mediates C3-independent docking of properdin that activates the alternative pathway of complement. ELife, 2020, 9, .	2.8	15
388	Innate immunity in the Aegean: ancient pathways for today's survival. Developmental and Comparative Immunology, 2002, 26, 217-225.	1.0	14
389	Complement Deposits on Ocular Tissues Adjacent to Sites of Inflammation. Current Eye Research, 2007, 32, 917-922.	0.7	14
390	CD59 Efficiently Protects Human NT2â€N Neurons Against Complementâ€mediated Damage. Scandinavian Journal of Immunology, 2007, 66, 345-351.	1.3	14
391	Hypoxia and reoxygenation of primary human hepatocytes induce proteome changes of glucose metabolism, oxidative protection and peroxisomal function. International Journal of Molecular Medicine, 2010, 26, 577-84.	1.8	14
392	A Phase-Variable Surface Layer from the Gut Symbiont Bacteroides thetaiotaomicron. MBio, 2015, 6, e01339-15.	1.8	14
393	From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology, 2016, 221, 1046-1057.	0.8	14
394	Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40. Clinical Immunology, 2016, 162, 37-44.	1.4	14
395	Factor H C-Terminal Domains Are Critical for Regulation of Platelet/Granulocyte Aggregate Formation. Frontiers in Immunology, 2017, 8, 1586.	2.2	14
396	A complement receptor C5a antagonist regulates epithelial to mesenchymal transition and crystallin expression after lens cataract surgery in mice. Molecular Vision, 2011, 17, 949-64.	1.1	14

#	Article	IF	Citations
397	Considering innate immune responses in SARS-CoV-2 infection and COVID-19. Nature Reviews Immunology, 2022, 22, 465-470.	10.6	14
398	Coupling of C3b to erythrocytes by disulfide bond formation: Preparation of EC3b for hemolytic and complement receptor assays. Journal of Immunological Methods, 1983, 65, 277-283.	0.6	13
399	Conjugation to Albuminâ€Binding Molecule Tags as a Strategy to Improve Both Efficacy and Pharmacokinetic Properties of the Complement Inhibitor Compstatin. ChemMedChem, 2014, 9, 2223-2226.	1.6	13
400	Combined Inhibition of Complement and CD14 Attenuates Bacteria-Induced Inflammation in Human Whole Blood More Efficiently Than Antagonizing the Toll-like Receptor 4â€“MD2 Complex. Journal of Infectious Diseases, 2016, 214, 140-150.	1.9	13
401	Complement C3 inhibitor Cp40 attenuates xenoreactions in pigÂhearts perfused with human blood. Xenotransplantation, 2017, 24, e12262.	1.6	13
402	Inhibition of Herpes Simplex Virus gD and Lymphotoxin-Î± Binding to HveA by Peptide Antagonists. Journal of Virology, 1999, 73, 5681-5687.	1.5	13
403	To Regeneration ... with Complement. Advances in Experimental Medicine and Biology, 2006, 586, 63-70.	0.8	12
404	Conformational analysis of compstatin analogues with molecular dynamics simulations in explicit water. Journal of Molecular Graphics and Modelling, 2007, 26, 571-580.	1.3	12
405	Anti-inflammatory effects of C1-Inhibitor in porcine and human whole blood are independent of its protease inhibition activity. Innate Immunity, 2010, 16, 254-264.	1.1	12
406	Complement therapeutics. Seminars in Immunology, 2016, 28, 205-207.	2.7	12
407	Overexpression, purification, and characterization of third component of complement. Journal of Immunological Methods, 1994, 176, 127-139.	0.6	11
408	A simple, yet highly accurate, QSAR model captures the complement inhibitory activity of compstatin. Bioorganic and Medicinal Chemistry, 2007, 15, 1638-1644.	1.4	11
409	Development of a New Pharmacophore Model That Discriminates Active Compstatin Analogs. Chemical Biology and Drug Design, 2008, 72, 249-256.	1.5	11
410	Selective inhibition of TNF-Î± or IL-1Î² does not affect E. coli-induced inflammation in human whole blood. Molecular Immunology, 2010, 47, 1774-1782.	1.0	11
411	Activation of Polymorphonuclear Leukocytes by Candidate Biomaterials for an Implantable Glucose Sensor. Journal of Diabetes Science and Technology, 2011, 5, 1490-1498.	1.3	11
412	Interventional treatment of renal angiomyolipoma: immediate results and clinical and radiological follow-up of 4.5 years. Acta Radiologica Open, 2015, 4, 205846011559244.	0.3	11
413	Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. Molecular Therapy - Oncolytics, 2016, 3, 16027.	2.0	11
414	Taming hemodialysis-induced inflammation: Are complement C3 inhibitors a viable option?. Clinical Immunology, 2019, 198, 102-105.	1.4	11

#	Article	IF	Citations
415	Thirty-Eight-Negative Kinase 1 Is a Mediator of Acute Kidney Injury in Experimental and Clinical Traumatic Hemorrhagic Shock. Frontiers in Immunology, 2020, 11, 2081.	2.2	11
416	Progress and trends in complement therapeutics. Advances in Experimental Medicine and Biology, 2013, 735, 1-22.	0.8	11
417	Activation of the Alternative Pathway of Human Complement by the Extracellular Slime Glycolipoprotein of Pseudomonas aeruginosa. Journal of Infectious Diseases, 1982, 145, 78-82.	1.9	10
418	From atoms to systems: a cross-disciplinary approach to complement-mediated functions*1. Molecular Immunology, 2004, 41, 153-164.	1.0	10
419	Structure-Based Integrative Computational and Experimental Approach for the Optimization of Drug Design. Lecture Notes in Computer Science, 2005, , 680-688.	1.0	10
420	Crystallization of human complement component C3b in the presence of a staphylococcal complement-inhibitor protein (SCIN). Acta Crystallographica Section F: Structural Biology Communications, 2009, 65, 482-485.	0.7	10
421	Short Leucine-Rich Proteoglycans Modulate Complement Activity and Increase Killing of the Respiratory Pathogen Moraxella catarrhalis. Journal of Immunology, 2018, 201, 2721-2730.	0.4	10
422	Complement Inhibitors Targeting C3, C4, and C5. , 0, , 75-112.		10
423	Complement in Action: An Analysis of Patent Trends from 1976 Through 2011. Advances in Experimental Medicine and Biology, 2013, 735, 301-313.	0.8	9
424	Attenuation of Staphylococcus aureusâ€“Induced Bacteremia by Human Mini-Antibodies Targeting the Complement Inhibitory Protein Efb. Journal of Immunology, 2015, 195, 3946-3958.	0.4	9
425	Reduced Terminal Complement Complex Formation in Mice Manifests in Low Bone Mass and Impaired Fracture Healing. American Journal of Pathology, 2019, 189, 147-161.	1.9	9
426	C3-targeted host-modulation approaches to oral inflammatory conditions. Seminars in Immunology, 2022, 59, 101608.	2.7	9
427	Functional maturation of murine B lymphocyte precursorsâ€”III. Soluble factors involved in the regulation of growth and differentiation. Molecular Immunology, 1988, 25, 1113-1127.	1.0	8
428	Complement and Neutrophil Function Changes After Liver Resection in Humans. World Journal of Surgery, 2009, 33, 2635-2643.	0.8	8
429	Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1041-1042, 19-26.	1.2	8
430	C5a-C5aR1 Axis Activation Drives Envenomation Immunopathology by the Snake Naja annulifera. Frontiers in Immunology, 2021, 12, 652242.	2.2	8
431	Complement component C3aR constitutes a novel regulator for chick eye morphogenesis. Developmental Biology, 2017, 428, 88-100.	0.9	8
432	A method for analysing lymphocyte surface antigens. Journal of Immunological Methods, 1980, 34, 287-293.	0.6	7

#	Article	IF	Citations
433	Novel Immunoassay for Complement Activation by PF4/Heparin Complexes. Thrombosis and Haemostasis, 2018, 118, 1484-1487.	1.8	7
434	â€˜Stealthâ€™ corporate innovation: an emerging threat for therapeutic drug development. Nature Immunology, 2019, 20, 1409-1413.	7.0	7
435	Regulation of Immune Responsiveness In VivoÂby Disrupting an Early T-Cell Signaling Event Using a Cell-Permeable Peptide. PLoS ONE, 2013, 8, e63645.	1.1	7
436	Phylogeny of the Third Complement Component, C3, and Conservation of C3-Ligand Interactions. Annals of the New York Academy of Sciences, 1994, 712, 354-357.	1.8	6
437	Expression of the third component of complement, C3, in regenerating limb blastema cells of urodeles. Molecular Immunology, 1998, 35, 372.	1.0	6
438	Modulation of fluid-phase complement activation inhibits hyperacute rejection in a porcine-to-human xenograft model. Transplantation Proceedings, 2000, 32, 899-900.	0.3	6
439	A sweet spot to control complement-induced inflammation. Nature Medicine, 2012, 18, 1340-1341.	15.2	6
440	Native state of complement protein C3d analysed via hydrogen exchange and conformational sampling. International Journal of Computational Biology and Drug Design, 2018, 11, 90.	0.3	6
441	Hydrogen/Deuterium Exchange Mass Spectrometry:Potential for Investigating Innate Immunity Proteins. , 2007, 598, 407-417.		6
442	Efficacy matters: broadening complement inhibition in COVID-19. Lancet Rheumatology, The, 2021, 3, e95.	2.2	6
443	Editorial: Therapeutic Modulation of the Complement System: Clinical Indications and Emerging Drug Leads. Frontiers in Immunology, 2019, 10, 3029.	2.2	6
444	Compstatin Inhibits Complement and Cellular Activation in Whole Blood in Two Models of Extracorporeal Circulation. Blood, 1998, 92, 1661-1667.	0.6	6
445	Regulation of Human Cytotoxic Responses by Complement: C3, C3b and C3d Preparations Enhance Human Allogeneic Cytotoxic Responses. Immunopharmacology and Immunotoxicology, 1986, 8, 529-541.	1.1	5
446	Isolation and characterization of the third complement component of axolotl (Ambystoma) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 227 Tc 839-845.	0.2	5
447	Multiâ€scale characterization of the energy landscape of proteins with application to the C3D/Efbâ€€ complex. Proteins: Structure, Function and Bioinformatics, 2010, 78, 1004-1014.	1.5	5
448	Air Bubbles Activate Complement and Trigger Hemostasis and C3-Dependent Cytokine Release Ex Vivo in Human Whole Blood. Journal of Immunology, 2021, 207, 2828-2840.	0.4	5
449	Application of the C3 inhibitor compstatin in a human whole blood model designed for complement research â€“ 20 years of experience and future perspectives. Seminars in Immunology, 2022, 59, 101604.	2.7	5
450	Bothrops jararaca Snake Venom Inflammation Induced in Human Whole Blood: Role of the Complement System. Frontiers in Immunology, 2022, 13, .	2.2	5

#	Article	IF	Citations
451	Emerging opportunities for C3 inhibition in the eye. Seminars in Immunology, 2022, 59, 101633.	2.7	5
452	Identification of three forms of iC3b that have distinct structures and receptor binding site properties. Molecular Immunology, 1982, 19, 1399.	1.0	4
453	Inducing and Characterizing Liver Regeneration in Mice: Reliable Models, Essential â€œReadoutsâ€•and Critical Perspectives. Current Protocols in Mouse Biology, 2013, 3, 141-170.	1.2	4
454	Preformed mediators of defenseâ€”Gatekeepers enter the spotlight. Immunological Reviews, 2016, 274, 5-8.	2.8	4
455	Complement C5a-Mediated TAM-ing of Antitumor Immunity Drives Squamous Carcinogenesis. Cancer Cell, 2018, 34, 531-533.	7.7	4
456	Cross-Disciplinary Research Stirs New Challenges into the Study of the Structure, Function and Systems Biology of Complement. Advances in Experimental Medicine and Biology, 2006, 586, 1-16.	0.8	4
457	Differentiation-dependent changes in human trophoblast expression of decay-accelerating factor are modulated by 3?,5? cyclic adenosine monophosphate. Journal of the Society for Gynecologic Investigation, 1997, 4, 47-53.	1.9	4
458	Structure, Dynamics, Activity, and Function of Compstatin and Design of More Potent Analogues. , 2005, , 317-340.		4
459	Fluorescent labelling of proteins of lymphocyte plasma membranes. Journal of Immunological Methods, 1979, 27, 55-59.	0.6	3
460	Importance of Factors H and I for the Adherence of C3b-Coated Erythrocytes to Cells. Immunobiology, 1983, 165, 211-224.	0.8	3
461	Cloning of three trout C3 isoforms: structural, functional, and phylogenetic analysis. Molecular Immunology, 1998, 35, 370.	1.0	3
462	Effect of a Putative B Cell Superantigen on Complement. Annals of the New York Academy of Sciences, 1995, 764, 356-358.	1.8	3
463	Poly-cation containing alginate microcapsules induce cytokines by a complement-dependent mechanism. Immunobiology, 2012, 217, 1221.	0.8	3
464	Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS) Centroid Data Measured between 3.6 Â°C and 25.4 Â°C for the Fab Fragment of NISTmAb. Journal of Research of the National Institute of Standards and Technology, 2019, 124, 1-7.	0.4	3
465	Structure, Dynamics, Activity, and Function of Compstatin and Design of More Potent Analogues. , 2005, , 317-340.		3
466	Similarities between a conserved sequence element of homoeo boxes and other genes. FEBS Letters, 1986, 194, 263-266.	1.3	2
467	Correction: Protection of nonself surfaces from complement attack by factor h-binding peptides: implications for therapeutic medicine. Journal of Immunology, 2012, 188, 6425-6425.	0.4	2
468	A 'rule of 3' to revive Greek science, research and innovation. Nature Immunology, 2015, 16, 1206-1208.	7.0	2

#	Article	IF	Citations
469	Complement C3 activation in the ICU: Disease and therapy as Bonnie and Clyde. Seminars in Immunology, 2022, 60, 101640.	2.7	2
470	Protein component of Pseudomonas aeruginosa slime glycolipoprotein in relation to laboratory-induced resistance to gentamicin. Canadian Journal of Microbiology, 1980, 26, 852-853.	0.8	1
471	Mechanisms of Action of Differentiation Inducers: Detection of Inducer Binding Protein(s) in Murine Erythroleukemia Cells. Oncology Research, 2005, 15, 21-37.	0.6	1
472	Identification of complement-targeting peptides using phage-display libraries. Molecular Immunology, 2008, 45, 4180-4181.	1.0	1
473	A flow-through optical sensor system for label-free detection of proteins and DNA. , 2009, , .		1
474	Cholesterol crystals activate the complement system and are phagocytosed in a complement-dependent manner. Molecular Immunology, 2013, 56, 246.	1.0	1
475	The effect of complement inhibition on erythrocyte destruction in AIHA. Molecular Immunology, 2017, 89, 203.	1.0	1
476	Interaction of Streptococcus pyogenes with extracellular matrix components resulting in immunomodulation and bacterial eradication. Matrix Biology Plus, 2020, 6-7, 100020.	1.9	1
477	Complement as a target in COVID-19?. , 0, .		1
478	Preclinical Development and In Vivo Evaluation Of Next-Generation Compstatin Analogs With Improved Systemic Profiles: A Novel Option For The Treatment Of Paroxysmal Nocturnal Hemoglobinuria. Blood, 2013, 122, 1239-1239.	0.6	1
479	The Building Blocks of the Complement System. , 2005, , 1-18.		1
480	Distinct role of complement anaphylatoxin receptors C5aR and C3aR in obese adipose tissue inflammation and insulin resistance. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	0.6	1
481	Complement C3 as a Target of Host Modulation in Periodontitis. , 2020, , 13-29.		1
482	Complement Receptors (CR) and Cytotoxic Responses: Monoclonal Antibodies Directed Against CR1 AMD CR3 Inhibit the Generation of Human Allospecific and Virus Specific Cytotoxic Cells in Vitro. Immunopharmacology and Immunotoxicology, 1986, 8, 75-88.	1.1	0
483	Mass spectrometric analyses of the activation products of the third component of complement. Techniques in Protein Chemistry, 1996, 7, 81-91.	0.3	0
484	Inhibition of complement and xenogeneic endothelial cell activation by compstation. Molecular Immunology, 1998, 35, 372.	1.0	0
485	Mass spectrometric analysis of the activation and expression products of the third component of complement (C3). Molecular Immunology, 1998, 35, 373.	1.0	0
486	160. Innate Immune Responses to Viral Vectors Are Modulated by Complement Inhibitors in an Ex Vivo Model Using Whole Human Blood. Molecular Therapy, 2006, 13, S62-S63.	3.7	0

#	Article	IF	Citations
487	Structureâ€“activity-based design of potent compstatin analogs. Molecular Immunology, 2007, 44, 192.	1.0	0
488	First identification of a chemotactic receptor in an invertebrate species: Structural and functional characterization of Ciona intestinalis C3a receptor. Molecular Immunology, 2007, 44, 238-239.	1.0	0
489	Effect of supraphysioloogic levels of C1-inhibitor on the classical, lectin, and alternative pathways of complement. Molecular Immunology, 2007, 44, 254.	1.0	0
490	A novel complement evasion mechanism of Staphylococcus aureus using Efb. Molecular Immunology, 2007, 44, 3926.	1.0	0
491	Novel insights into target specificities and molecular mechanisms for two potent complement evasion proteins from Staphylococcus aureus. Molecular Immunology, 2008, 45, 4114-4115.	1.0	0
492	Genetic complement deficiencies dissociate the roles of human complement in the inflammatory responses: Lessons from nature. Molecular Immunology, 2008, 45, 4145-4146.	1.0	0
493	A C3 inhibitor on its way to clinical applications: Novel developments in compstatin activity and function. Molecular Immunology, 2008, 45, 4180.	1.0	0
494	Key role of complement receptor 1 in the initial binding of Escherichia coli and Neisseria meningitidis to erythrocytes in human whole blood. Molecular Immunology, 2009, 46, 2824.	1.0	0
495	Binding of complement proteins to activated platelets is independent of complement activation. Molecular Immunology, 2009, 46, 2853.	1.0	0
496	Key role of CD14 in the E. coli- and LPS-induced mRNA down regulation of the C5a receptors CD88 and C5L2. Molecular Immunology, 2010, 47, 2241-2241.	1.0	0
497	Characterization of the interactions between C3b and complement regulators. Molecular Immunology, 2010, 47, 2259-2259.	1.0	0
498	Contribution of chondroitin sulfate A to the binding of complement proteins to activated platelets. Molecular Immunology, 2010, 47, 2222-2222.	1.0	0
499	Ornithodoros moubata complement inhibitor (OmCI) is an equally effective C5 inhibitor in pig and human, and combined with CD14 inhibition, efficiently attenuate Escherichia coli-induced sepsis in pigs. Molecular Immunology, 2011, 48, 1699.	1.0	0
500	Diversity in the C3b contact residues and tertiary structures of the staphylococcal complement inhibitor (SCIN) protein family.. Journal of Biological Chemistry, 2012, 287, 9329.	1.6	0
501	Preface. Immunobiology, 2012, 217, 1025.	0.8	0
502	Autoregulation of thromboinflammation on biomaterials and cells by a novel therapeutic coating technique. Immunobiology, 2012, 217, 1140.	0.8	0
503	Complement anaphylatoxin C5a supports ovarian cancer development and controls the expression of VEGF164/165 isoforms. Immunobiology, 2012, 217, 1155.	0.8	0
504	Complement in action: An analysis of patent trends from 1976 through 2011. Immunobiology, 2012, 217, 1157-1158.	0.8	0

#	Article	IF	Citations
505	Complement pathways in periodontitis and targeted therapeutic intervention. Immunobiology, 2012, 217, 1159.	0.8	0
506	Complement receptor C3aR modulates platelet function and thrombosis. Immunobiology, 2012, 217, 1160.	0.8	0
507	Compstatin induces allosteric changes in C3 and C3b and changes their ligand binding pattern. Immunobiology, 2012, 217, 1160.	0.8	0
508	On the conformational flexibility of C3b: A molecular insight into activation and transformation of a major complement effector. Immunobiology, 2012, 217, 1192.	0.8	0
509	Phagocytosis of Escherichia coli in human whole blood: Early complement dependency is succeeded by late CD14 dependency over time. Immunobiology, 2012, 217, 1193.	0.8	0
510	The role of properdin in zymosan- and Escherichia coli-induced complement activation. Immunobiology, 2012, 217, 1212.	0.8	0
511	Structural insights into cofactor activity. Immunobiology, 2016, 221, 1193.	0.8	0
512	Mechanistic evidence for incomplete terminal pathway inhibition under eculizumab during strong complement activation. Immunobiology, 2016, 221, 1216.	0.8	0
513	Complement activation fragment C4a acts as effector molecule by signaling via protease-activated receptors 1 and 4. Molecular Immunology, 2017, 89, 130.	1.0	0
514	Intravascular complement activation on neutrophils initiates the inflammatory cascade. Molecular Immunology, 2018, 102, 198.	1.0	0
515	Response to â€œComment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19â€• Clinical Immunology, 2021, 222, 108617.	1.4	0
516	Structure of the Anaphylatoxins C3a and C5a. , 2005, , 161-177.		0
517	Thrombin as a C5 Convertase. FASEB Journal, 2006, 20, A641.	0.2	0
518	Dietâ€induced hepatocellular carcinoma in geneticallyâ€predisposed mice. FASEB Journal, 2009, 23, LB508.	0.2	0
519	Complement inhibition decreases the fibrotic response in septic baboons. FASEB Journal, 2011, 25, 114.7.	0.2	0
520	Abstract 2413: Diet-induced non-alcoholic steatohepatitis and hepatocellular carcinoma in chromosome substitution strains of mice. , 2011, , .		0
521	Novel Complement Modulators for Paroxysmal Nocturnal Hemoglobinuria: Peptide and Protein Inhibitors of C3 Convertase Prevent Both Surface C3 Deposition and Subsequent Hemolysis of Affected Erythrocytes in Vitro. Blood, 2012, 120, 370-370.	0.6	0